ATEC
BEARISH
$15.62
Live
Alphatec Holdings, Inc. · NASDAQ
Target $24.92
(+59.6%)
$8.81
52W Range
$23.29
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$2.32B
P/E
N/A
ROE
-540.4%
Profit margin
-21.3%
Debt/Equity
16.84
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
68%
The Advanced Deterministic Scorecard reveals significant concerns with a Piotroski F-Score of 4/9, indicating borderline financial health, and the absence of an Altman Z-Score prevents a full solvency assessment. Despite strong revenue growth of 30.4% and a bullish analyst recommendation (strong_buy), the company is unprofitable with a -21.29% profit margin and an alarming ROE of -540.41%. High valuation multiples, including a Price/Book of 200.26 and Forward P/E of 79.16, are not supported by current earnings or cash flow, while insider selling of $55.28M in the last six months signals strong bearish sentiment from management. Technical trend is bearish, and recent price performance shows a sharp 1-month decline of -24.8%, suggesting weakening momentum.
Key Strengths
Strong year-over-year revenue growth of 30.40% outpaces sector average of 23.74%
High gross margin of 69.23% indicates strong pricing power and cost control in core operations
Recent earnings surprises have been positive, with 3 out of last 4 quarters beating estimates and an average surprise of 136.19%
Analyst consensus is strong_buy with a high target price of $24.92, implying 59.6% upside
Current ratio of 1.99 suggests adequate short-term liquidity
Key Risks
Piotroski F-Score of 4/9 indicates weak financial health with multiple red flags in profitability and leverage
Extremely high debt/equity ratio of 16.84, vastly exceeding sector average of 1.03, signaling severe financial risk
Negative ROE (-540.41%) and negative profit margin (-21.29%) reflect deep unprofitability and poor capital efficiency
Insiders have sold $55.28M in shares over the last 6 months with zero buy transactions, indicating strong bearish sentiment
Price/Book of 200.26 and Forward P/E of 79.16 suggest extreme overvaluation relative to book value and earnings
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
27
Weak
15
60
40
20
0
AI Verdict
High-risk speculative position with unsustainable valuation and weak fundamentals
Key drivers: Negative profitability metrics, Extreme leverage (Debt/Equity = 16.84), Overvalued metrics (P/B = 200.26), Bearsish insider activity, Lack of Altman Z-Score for solvency assessment
Confidence
70%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
- Analyst target price implies upside
Watchpoints
- Price/Book of 200.26 is extremely high
- Forward P/E of 79.16 not justified by current earnings
- No Graham Number or Intrinsic Value available
- P/E is N/A due to negative earnings
Future
60/100
Ref Growth rates
Positives
- Revenue growth (YoY) of 30.40% is strong
- EPS YoY growth of +123.1% and Q/Q of +50.0% show improving earnings trajectory
- Analysts project strong future performance
Watchpoints
- Earnings growth is off a negative base, limiting sustainability
- No free cash flow or operating cash flow data available
Past
40/100
Ref Historical trends
Positives
- Recent quarters show consistent positive earnings surprises
- Revenue trend has improved significantly over past year
Watchpoints
- Long history of negative earnings and margins
- ROA of -6.00% indicates poor asset utilization
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 1.99 indicates short-term liquidity
- Quick ratio of 1.16 is above 1, suggesting some cushion
Watchpoints
- Piotroski F-Score of 4/9 indicates weak financial health
- Debt/Equity of 16.84 is dangerously high
- ROE of -540.41% reflects severe equity destruction
- No Altman Z-Score available for distress risk assessment
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100
- No dividend yield or payout history
- No capacity to pay dividends given unprofitability
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$15.62
Analyst Target
$24.92
Upside/Downside
+59.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ATEC and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ATEC
Alphatec Holdings, Inc.
Primary
|
+4.7% | +20.4% | +33.9% | +44.4% | -24.8% | -11.9% |
|
HTFL
Heartflow, Inc.
Peer
|
-10.1% | -10.1% | -10.1% | -19.5% | +21.3% | +8.5% |
|
NKTR
Nektar Therapeutics
Peer
|
-72.0% | +482.5% | +802.9% | +42.4% | +12.5% | +6.6% |
|
XRAY
DENTSPLY SIRONA Inc.
Peer
|
-80.0% | -68.7% | -7.0% | -8.3% | +3.8% | -1.6% |
|
SRPT
Sarepta Therapeutics, Inc.
Peer
|
-69.3% | -82.8% | -59.9% | -4.3% | +25.6% | +1.8% |
ATE
Alphatec Holdings, Inc.
Primary
5Y
+4.7%
3Y
+20.4%
1Y
+33.9%
6M
+44.4%
1M
-24.8%
1W
-11.9%
HTF
Heartflow, Inc.
Peer
5Y
-10.1%
3Y
-10.1%
1Y
-10.1%
6M
-19.5%
1M
+21.3%
1W
+8.5%
NKT
Nektar Therapeutics
Peer
5Y
-72.0%
3Y
+482.5%
1Y
+802.9%
6M
+42.4%
1M
+12.5%
1W
+6.6%
XRA
DENTSPLY SIRONA Inc.
Peer
5Y
-80.0%
3Y
-68.7%
1Y
-7.0%
6M
-8.3%
1M
+3.8%
1W
-1.6%
SRP
Sarepta Therapeutics, Inc.
Peer
5Y
-69.3%
3Y
-82.8%
1Y
-59.9%
6M
-4.3%
1M
+25.6%
1W
+1.8%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
79.16
PEG Ratio
N/A
P/B Ratio
200.26
P/S Ratio
3.19
EV/Revenue
3.82
EV/EBITDA
583.78
Market Cap
$2.32B
Profitability
Profit margins and return metrics
Profit Margin
-21.29%
Operating Margin
-4.79%
Gross Margin
69.23%
ROE
-540.4%
ROA
-6.0%
Growth
Revenue and earnings growth rates
Revenue Growth
+30.4%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
16.84
High debt
Current Ratio
1.99
Good
Quick Ratio
1.16
Good
Cash/Share
$1.05
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-24
$N/A
2025-10-30
$0.03
+233.4% surprise
2025-07-31
$0.02
+148.0% surprise
2025-05-01
$-0.09
+27.2% surprise
Healthcare Sector Comparison
Comparing ATEC against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-540.4%
This Stock
vs
-88.14%
Sector Avg
+513.1%
(Excellent)
Profit Margin
-21.29%
This Stock
vs
-16.28%
Sector Avg
+30.7%
(Superior)
Debt to Equity
16.84
This Stock
vs
2.66
Sector Avg
+532.5%
(Higher)
Revenue Growth
30.4%
This Stock
vs
124.04%
Sector Avg
-75.5%
(Slower)
Current Ratio
1.99
This Stock
vs
4.47
Sector Avg
-55.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ATEC
Alphatec Holdings, Inc.
|
BEARISH | $2.32B | - | -540.4% | -21.3% | $15.62 | |
|
HTFL
Heartflow, Inc.
|
BEARISH | $2.31B | - | -111.4% | -66.3% | $26.95 | Compare |
|
NKTR
Nektar Therapeutics
|
BEARISH | $2.33B | - | -217.9% | -297.1% | $81.26 | Compare |
|
XRAY
DENTSPLY SIRONA Inc.
|
BEARISH | $2.38B | - | -36.4% | -16.2% | $11.9 | Compare |
|
SRPT
Sarepta Therapeutics, Inc.
|
BEARISH | $2.26B | - | -53.5% | -32.5% | $21.55 | Compare |
ATEC
Alphatec Holdings, Inc.
BEARISH
Mkt Cap
$2.3B
P/E
-
ROE
-540.4%
Price
$15.62
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-05 | MILES PATRICK S | Chief Executive Officer | Sale | 100,000 | $2,101,000 |
| 2025-12-16 | PELIZZON DAVID R | Director | Sale | 250,000 | $4,915,000 |
| 2025-12-16 | LISH SCOTT | Chief Operating Officer | Sale | 19,900 | $390,836 |
| 2025-12-11 | DEMSKI DAVID M | Director | Sale | 30,000 | $636,000 |
| 2025-12-10 | HUNSAKER CRAIG E | Officer | Sale | 32,584 | $679,051 |
| 2025-12-10 | SPONSEL DAVID | Officer | Sale | 21,106 | $438,794 |
| 2025-12-09 | PRITZKER JENNIFER N | Beneficial Owner of more than 10% of a Class of Security | Sale | 250,000 | $5,295,098 |
| 2025-12-09 | SQUADRON CAPITAL HOLDINGS LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | 250,000 | $5,295,098 |
| 2025-12-09 | SQUADRON CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | 250,000 | $5,295,098 |
| 2025-12-09 | PELIZZON DAVID R | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | 250,000 | $5,295,098 |
| 2025-12-08 | SPONSEL DAVID | Officer | Sale | 988 | $21,193 |
| 2025-12-05 | MARSHALL TYSON ELIOT | General Counsel | Sale | 22,889 | $491,526 |
| 2025-12-05 | LISH SCOTT | Chief Operating Officer | Sale | 10,875 | $233,486 |
| 2025-12-01 | MILES PATRICK S | Chief Executive Officer | Sale | 100,000 | $2,211,000 |
| 2025-11-24 | PRITZKER JENNIFER N | Beneficial Owner of more than 10% of a Class of Security | Sale | 250,000 | $5,155,000 |
MILES PATRICK S
Chief Executive Officer
2026-01-05
100,000 shares
·
$2,101,000
PELIZZON DAVID R
Director
2025-12-16
250,000 shares
·
$4,915,000
LISH SCOTT
Chief Operating Officer
2025-12-16
19,900 shares
·
$390,836
DEMSKI DAVID M
Director
2025-12-11
30,000 shares
·
$636,000
HUNSAKER CRAIG E
Officer
2025-12-10
32,584 shares
·
$679,051
SPONSEL DAVID
Officer
2025-12-10
21,106 shares
·
$438,794
PRITZKER JENNIFER N
Beneficial Owner of more than 10% of a Class of Security
2025-12-09
250,000 shares
·
$5,295,098
SQUADRON CAPITAL HOLDINGS LLC
Beneficial Owner of more than 10% of a Class of Security
2025-12-09
250,000 shares
·
$5,295,098
SQUADRON CAPITAL, L.L.C.
Beneficial Owner of more than 10% of a Class of Security
2025-12-09
250,000 shares
·
$5,295,098
PELIZZON DAVID R
Director and Beneficial Owner of more than 10% of a Class of Security
2025-12-09
250,000 shares
·
$5,295,098
SPONSEL DAVID
Officer
2025-12-08
988 shares
·
$21,193
MARSHALL TYSON ELIOT
General Counsel
2025-12-05
22,889 shares
·
$491,526
LISH SCOTT
Chief Operating Officer
2025-12-05
10,875 shares
·
$233,486
MILES PATRICK S
Chief Executive Officer
2025-12-01
100,000 shares
·
$2,211,000
PRITZKER JENNIFER N
Beneficial Owner of more than 10% of a Class of Security
2025-11-24
250,000 shares
·
$5,155,000
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
13 analysts
Needham
2026-01-12
Buy
Buy
HC Wainwright & Co.
2026-01-12
Buy
Buy
Barclays
2026-01-07
Overweight
Overweight
Freedom Capital Markets
2025-12-11
Buy
Morgan Stanley
2025-11-10
Equal-Weight
Equal-Weight
Barclays
2025-11-03
Overweight
Overweight
Canaccord Genuity
2025-10-31
Buy
Buy
Piper Sandler
2025-10-31
Overweight
Overweight
Stifel
2025-10-31
Buy
Buy
HC Wainwright & Co.
2025-10-31
Buy
Buy
Past News Coverage
Recent headlines mentioning ATEC from our newsroom.
Newest → oldest
No matching news yet.